DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Phase 2

Completed

Conditions: Islet Cell Tumor
Neuroendocrine Tumor

Interventions: Drug: Sunitinib malate
Procedure: Hepatic Artery Embolizations

First Posted Date: 2007-02-12

Last Posted Date: 2012-09-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 39

Registration Number: NCT00434109

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Liposarcoma
Leiomyosarcoma
Fibrosarcoma
Malignant Fibrous Histiocytoma

Interventions: Drug: Sunitinib Malate (SU011248)

First Posted Date: 2006-11-17

Last Posted Date: 2012-08-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 48

Registration Number: NCT00400569

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Azacitidine

First Posted Date: 2006-10-13

Last Posted Date: 2014-08-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT00387647

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Patient Navigator Project

Not Applicable

Completed

Conditions: Breast Cancer
Colon Cancer

Interventions: Procedure: Patient Navigation
Procedure: Clinic Staff

First Posted Date: 2006-09-12

Last Posted Date: 2012-11-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 1267

Registration Number: NCT00375024

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma

Phase 2

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Biological: Dendritic Cell (DC) Injections
Procedure: Radiation therapy
Procedure: Complete Resection - Surgery for tumor removal

First Posted Date: 2006-08-18

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 17

Registration Number: NCT00365872

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

Phase 2

Terminated

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: Temozolomide

First Posted Date: 2006-08-17

Last Posted Date: 2009-01-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 1

Registration Number: NCT00365222

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: suberoylanilide hydroxamic acid (SAHA, Vorinostat)
Drug: tamoxifen citrate (Tamoxifen)

First Posted Date: 2006-08-17

Last Posted Date: 2014-11-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 43

Registration Number: NCT00365599

Locations: 🇺🇸
Bethesda Memorial Hospital Research Center, Boynton Beach, Florida, United States
🇺🇸
University of California, San Francisco, California, United States
🇺🇸
Martin Memorial Cancer Center, Stuart, Florida, United States

and more 5 locations

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

Not Applicable

Terminated

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: G-CSF
Drug: Leukapheresis
Drug: Busulfan
Procedure: Stem cell reinfusion

First Posted Date: 2006-08-15

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT00363467

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: PS-341
Drug: R11577

First Posted Date: 2006-08-07

Last Posted Date: 2013-11-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT00361088

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

Phase 2

Terminated

Conditions: Glioma
Oligodendroglioma
Astrocytoma

Interventions: Drug: Irinotecan Hydrochloride (HCI) Treatment
Drug: Continued Irinotecan Hydrochloride (HCI) Treatment

First Posted Date: 2006-08-07

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 10

Registration Number: NCT00360828

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy